Insulin glargine and its role in glycaemic management of Type 2 diabetes

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 8, 2008, Pages 1099-1110

  Elrishi, M A ^a   Jarvis, Janet ^a   Khunti, K ^b   Davies, M J ^c  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Basal insulin analogue; Hypoglycaemia; Insulin glargine; Type 2 diabetes mellitus

Indexed keywords

EXENDIN 4; GLIMEPIRIDE; GLITAZONE DERIVATIVE; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA;

BEDTIME DOSAGE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGENITAL MALFORMATION; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH CARE COST; HUMAN; HYPOGLYCEMIA; HYPOTENSION; MACROSOMIA; MONOTHERAPY; NAUSEA; NEWBORN MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT EDUCATION; PATIENT SATISFACTION; PREECLAMPSIA; PREGNANCY; QUALITY OF LIFE; RETINOPATHY; REVIEW; SIDE EFFECT; VOMITING; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

ALGORITHMS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 51049092920     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.4.8.1099     Document Type: Review

References (48)

1. Diabetes UK. Diabetes: State of the Nations 2005; progress made in delivering the national diabetes frameworks. Diabetes UK; 2005. 9435/ 1205/a
2. U.K. Prospective Diabetes Study Group. UKPDS 33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-53
3. Meneghini LF, Rosenberg KH, Koenen C, et al. Insulin detemir improves glycaemic control with less hypoglycaemia and weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine. Diabetes Obes Metab 2007;9:418-27
4. Rosenstock J, Davies M, Home PD, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008;51:408-16
5. Nathan DM. Finding new treatments for diabetes - how many, how fast...how good? N Eng J Med 2007;356(5):437-40
6. Barnett AH, Owens DR. Long-acting insulin analogues; insulin made easy. Revised Edition. Medical Education Partnership Ltd; 2004
7. Porcellati F, Rossetti P, Ricci Busciantella N, et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes mellitus: a double-blind, randomized, cross-over study. Diabetes Care 2007;30(10):2447-52
8. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin and ultralente human insulin and continuous subcutaneous insulin infusion of insulin lispro. Diabetes 2000;49:2142-8
9. Rosskamp R, Park G. Long-acting insulin analogues. Diabetes Care 1999;22(Suppl 2):109-13
10. Bolli GB, Di Marchi RD, Park GD, et al. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999; 42:1151-67
11. Hilgenfield R, Dorschung M, Geisen K, et al. Controlling insulin bioavailability by crystal contact engineering. Diabetologia 1992;35:A193
12. Heinemann L, Linkeschova R, Rave K, et al. Time action profile of the long-acting insulin analog insulin glargine in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23:644-9
13. Klein O, Lynge J, Endahl L, et al. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in Type 2 diabetes. Diabetes Obes Metab 2007;9(3):290-9
14. Porcellati F, Rossetti P, Busciantella NR, et al. Pharmacokinetics and phamacodynamics of the long-acting insulin analog glargine after one week of use compared with its first administration in subjects with type 1 diabetes. Diabetes Care 2007;30:1261-3
15. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 2007;9(5):648-59
16. Rosenstock J, Sugimoto D, Strange P, et al. on behalf of the Insulin Glargine 4014 Study investigators. Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006;29(3):554-9
17. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6
18. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006;49:442-51
19. Yki-Jarvinen H, Dressler A, Ziemen M; for the HOE 901/3005 Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000;23:1130-6
20. Massi Benedetti M, Humburg E, Dressler A, et al. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 2003;35:189-96
21. Mullins P, Sharplin P, Yki-Jarvinen H, et al. Negative binomial meta-regression analysis combined glycosylated haemoglobin and hypoglycaemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther 2007;29(8):1607-19
22. Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycaemia risk with insulin glargine. A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005;28(4):950-5
23. Rosenstock J, Schwartz SL, Clark CM, et al. Basal insulin therapy in type 2 diabetes: 28 week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631-6
24. National Institute of Clinical Excellence. Guidance on the use of long-acting insulin analogues for the treatment of diabetes - insulin glargine. Technology Appraisal Guidance No 53. December 2002. N0179 1P 50k Dec 02 (ABA)
25. Holman RR, Thorne KI, Framer AJ, et al. Addition of Biphasic, prandial or basal insulin to oral therapy in type 2 diabetes. N Eng J Med 2007;357(17):1716-30
26. Malone JK, Kerr LF, Campaigne BN, et al.; Lispro Mixture-Glargine Study Group. Combined therapy with insulin lispro mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label,crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004;26:2034-44
27. Malone JK, Bai S, Campaigne BN, et al. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes. Diabet Med 2005;22:374-81
28. Raskin P, Allen E, Hollander P, et al.; INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260-5
29. Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;28:254-9
30. Bretzel RG, Nuber U, Landgraf W, et al. Once daily basal insulin glargine versus thrice daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008;371:1073-84
31. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med 2005;143:559-69
32. Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulphonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007;29(11):2333-48
33. Secnik BK, Matza LS, Oglesby A, et al. Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health Qual Life Outcomes 2006;4:80
34. Yki-Jarvinen H, Juurinen L, Alvarsson M, et al. Initiate Insulin by Aggressive Titration and Education (INITIATE). A randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care 2007;30(6):1364-9
35. Davies M, Storms F, Shutler S, et al.; for the ATLANTUS Study Group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005;28:1282-8
36. Davies M, Evans R, Storms F, et al. Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK. Diabetes Obes Metab 2007;9(5):706-13
37. Vinik AI, Zhang Q. Adding insulin glargine versus rosiglitazone. Health-related quality-of-life impact in type 2 diabetes. Diabetes Care 2007;30:795-800
38. Kaplan W, Rodriguez LM, Smith OE, et al. Effects of mixing glargine and short-acting insulin analogs on glucose control. Diabetes Care 2004;27:2739-40
39. Standl E, Maxeiner S, Raptis S, et al. Good glycaemic control with flexibility in timing of basal insulin supply: a 24 week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride. Diabetes Care 2005;28:419-20
40. National Institute of Clinical Excellence. Diabetes in pregnancy, Management of diabetes and its complications from pre-conception to the postnatal period. NICE clinical guideline 63 developed by the National Collaborating Centre for Women's and Children's Health. March 2008
41. Hofmann T, Horstmann G, Stammberger I. Evaluation of the reproductive toxicity and embryotoxicity of insulin glargine (LANTUS) in rats and rabbits. Int J Toxicol 2002;21:181-9
42. Gallen IW, Jaap AJ, Roland JM, Chirayath HH. Survey of glargine use in 115 pregnant women with type 1 diabetes. Diabetic Med 2008;25:165-9
43. Price N, Bartlett C, Gillmer MD. Use of insulin glargine during pregnancy: a case-control pilot study. BJOG Int J Obstet Gynaecol 2007;114(4):453-7
44. Warren E, Weatherley-Jones E, Chilcott J, et al. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess 2004;8(45):1-57
45. McEwan P, Poole CD, Tetlow T, et al. Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK. Curr Med Res Opin 2007;23(Suppl 1):S21-31
46. Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH (human isophane insulin) for type 2 diabetes mellitus [review]. The Cochrane Library 2007. Issue 4
47. Papa G, Fedele V, Chiavetta A, et al. Therapeutic options for elderly diabetic subjects: Open label randomised clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs. Acta Diabetologica 2008;45:53-9
48. Janka HU, Plewe G, Busch K. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. J Am Geriatr Soc 2007;55:182-8